Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Hutchmed China Ltd ADR (NQ: HCM ) 18.47 -1.18 (-6.01%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Hutchmed China Ltd ADR < Previous 1 2 3 4 5 6 Next > Hutchmed scores U.S. success with cancer drug, but profits still dip August 15, 2024 Key Takeaways: Hutchmed’s U.S. sales jumped nearly 53% in the second quarter from the previous three months, boosted by uptake of the cancer drug Fruzaqla The company plans to focus on innovative drugs... Via Benzinga Why HUTCHMED Stock Is Moving Higher Friday July 05, 2024 HUTCHMED announced that its New Drug Application for Tazemetostat for the treatment of relapsed or refractory follicular lymphoma was accepted in China with Priority Review status. Via Benzinga Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday May 09, 2024 Via Benzinga Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion April 06, 2024 ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... Via Talk Markets Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session March 14, 2024 U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday. Via Benzinga Topics Stocks Exposures US Equities Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session March 13, 2024 Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session March 13, 2024 Via Benzinga Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket March 13, 2024 Shares of SurgePays, Inc. (NASDAQ: SURG) fell sharply in today’s pre-market trading after the company reported worse-than-expected fourth-quarter financial results. Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday March 13, 2024 Pre-market stock movers are a great way to start the day with all of the hottest news worth reading about on Wednesday morning! Via InvestorPlace Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session March 13, 2024 U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. Via Benzinga Airbnb Reports Q4 Results, Joins MGM Resorts, Upstart And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session February 14, 2024 U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 80 points on Wednesday. Via Benzinga Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets February 03, 2024 Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones. Via Talk Markets Broadcom To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday November 24, 2023 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Goldman Sachs Maintains Neutral Rating for HUTCHMED (China): Here's What You Need To Know November 10, 2023 Via Benzinga CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade November 08, 2023 On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier. Via Investor's Business Daily Rocket Pharmaceuticals Stock Sees Improved Price Strength November 02, 2023 On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78 Via Investor's Business Daily Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90 October 31, 2023 Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. Via Investor's Business Daily Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday October 30, 2023 U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session. Via Benzinga Topics Stocks Exposures US Equities Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session October 30, 2023 Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. Via Benzinga Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher October 27, 2023 A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue? Via Investor's Business Daily Chipotle, Amazon, Deckers Outdoor, Capital One And Other Stocks Move Higher On Friday October 27, 2023 U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session. Via Benzinga Topics Stocks Exposures US Equities Apellis Pharmaceuticals Stock Shows Rising Relative Strength October 24, 2023 A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue? Via Investor's Business Daily Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90 October 16, 2023 Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. Via Investor's Business Daily AZZ, VOXX International And Other Big Stocks Moving Higher On Wednesday October 11, 2023 U.S. stocks traded higher Wednesday, with the Dow Jones gaining around 100 points. Here are some big stocks recording gains in today’s session. Via Benzinga Topics Stocks Exposures US Equities Sarepta Therapeutics Stock Showing Rising Relative Strength October 09, 2023 Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating Via Investor's Business Daily Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark September 28, 2023 Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level. Via Investor's Business Daily Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating September 27, 2023 A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. Via Investor's Business Daily Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session September 11, 2023 U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. Via Benzinga Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca August 26, 2023 China’s drug distributors are in the hunt to acquire Poland’s Neuca, a company with a 32% market share of Poland’s pharmaceutical distribution business. The consortium of China’s drug distributors may... Via Talk Markets Hutchmed's Candidate Achieves Main Goal In China's Rare Blood Disorder Study August 21, 2023 HUTCHMED (China) Limited's (NASDAQ: HCM) pivotal Phase 3 trial ESLIM-01 evaluating the investigational use of sovleplenib met its primary endpoint of durable response rate and all secondary endpoints... Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.